Lyme Disease in Dogs: Borrelia burgdorferi Transmission and Clinical Signs

Introduction

Lyme borreliosis is a multisystemic arthropod-borne disease of dogs caused by the spirochete bacterium Borrelia burgdorferi sensu lato complex, primarily B. burgdorferi sensu stricto in North America and B. afzelii and B. garinii in Eurasia. The pathobiology of canine Lyme disease is distinct from human disease in several key aspects, including a lower incidence of clinical arthritis and a strong predilection for immune-mediated glomerulonephritis. Understanding the transmission dynamics mediated by Ixodes spp. ticks, the clinical spectrum of disease, and evidence-based vaccine protocols is essential for veterinary practitioners managing endemic regions. This review synthesizes current peer-reviewed literature on vector ecology, bacterial pathogenesis, and prophylactic strategies, with an emphasis on canine-specific manifestations.

Etiology and Vector Ecology

B. burgdorferi is a Gram-negative, microaerophilic spirochete with a complex life cycle that alternates between an ixodid tick vector and a mammalian reservoir host. The bacterium is maintained in enzootic cycles involving small rodents (e.g., Peromyscus leucopus) and birds, with dogs serving as incidental dead-end hosts despite their ability to sustain spirochetemia for several weeks. In a comprehensive survey of tick species and tick-borne pathogens in pet dogs and cats in mainland China, Ye et al. documented the presence of B. burgdorferi sensu lato in Ixodes persulcatus and Haemaphysalis longicornis, highlighting the expanding geographic range of competent vectors [1]. Similarly, a study of canine vector-borne diseases in Lebanon by Khalife and El Safadi identified B. burgdorferi seropositivity in dogs residing in peri-urban environments, underscoring the importance of regional risk factor profiling [2].

The principal vectors in North America are Ixodes scapularis (black-legged tick) in the eastern and midwestern United States and Ixodes pacificus (western black-legged tick) along the Pacific coast. In Europe, Ixodes ricinus is the dominant vector, while I. persulcatus predominates in Asia. Transmission of B. burgdorferi to the canine host requires tick attachment for a minimum of 24 to 48 hours, during which the spirochetes migrate from the tick midgut to the salivary glands and are inoculated into the dermis.

Transmission Dynamics

The acquisition and transmission of B. burgdorferi involve a series of molecular interactions between spirochete surface proteins and tick salivary components. The outer surface protein A (OspA) is expressed by B. burgdorferi while in the tick midgut and mediates adherence to the tick gut epithelium. As the tick takes a blood meal, environmental cues such as temperature and pH shifts cause the spirochete to downregulate OspA and upregulate OspC, which facilitates migration to the salivary glands and inoculation into the vertebrate host.

In a double-blinded, placebo-controlled field trial of an OspA-based oral reservoir targeted vaccine, Schwartz et al. demonstrated that reducing spirochete prevalence in reservoir populations can diminish transmission risk to incidental hosts [3]. This reservoir-targeted strategy complements direct canine vaccination by interrupting the enzootic cycle. The predictive modeling of Lyme disease risk using a One Health approach by McDermott et al. integrates environmental variables, tick phenology, and canine serosurveillance data to forecast transmission hotspots [4].

A study by Geurden et al. evaluated the efficacy of isoxazoline-based ectoparasiticides (Simparica and Simparica TRIO) in preventing B. burgdorferi transmission by I. scapularis in dogs, showing that rapid tick kill (within 8 to 12 hours of attachment) significantly reduced transmission compared to placebo-treated controls [7]. Similarly, Anderson et al. demonstrated that lotilaner-containing chewable tablets (Credelio Quattro) prevented transmission of B. burgdorferi from infected I. scapularis in a controlled laboratory challenge model [12]. The critical time window for transmission prevention underscores the importance of acaricidal prophylaxis in endemic areas.

Transmission Prevention Decision Diagram

flowchart TD
    A[Endemic area?], >|Yes| B[Monthly acaricide + vaccination]
    A, >|No| C[Travel history risk?]
    C, >|Yes| B
    C, >|No| D[Annual seroscreening + owner education]
    B, > E[Evaluate tick attachment duration]
    E, >|<48h| F[Doxycycline prophylaxis not routinely indicated]
    E, >|>=48h| G[Consider single dose doxycycline?]
    G, >|Pet high risk| H[Administer 10 mg/kg doxycycline once]
    G, >|Low risk| F
    F, > I[Monitor for clinical signs 2-4 weeks]
    I, > J[Clinical signs present?]
    J, >|Yes| K[Full diagnostic workup: C6 ELISA + PCR + urinalysis]
    J, >|No| L[Continue routine prevention]

Clinical Signs in Dogs

Unlike humans, only approximately 5 to 10 percent of seropositive dogs develop overt clinical signs. The most common clinical presentation is acute-onset lameness due to inflammatory polyarthropathy, typically affecting one or more joints. The lameness may be shifting, episodic, and accompanied by joint effusion, pain on manipulation, and reluctance to move. Fever, lethargy, and regional lymphadenopathy are frequently observed. In a study by Kloster et al. examining antibodies against tick-borne pathogens in domestic dogs in Norway, seroprevalence to B. burgdorferi sensu lato was 4.2 percent, though clinical borreliosis was rarely reported, suggesting that subclinical infection predominates in Scandinavian canine populations [6].

Renal manifestations constitute the most serious complication of canine Lyme disease. Lyme nephritis is characterized by protein-losing nephropathy, azotemia, and progressive renal failure. Histopathologically, the condition is a membranoproliferative glomerulonephritis with deposition of immune complexes containing Borrelia antigens. The pathogenesis is believed to involve cross-reactive antibodies directed against the spirochete's outer surface proteins that bind to glomerular basement membrane components.

Neurologic signs are uncommon in dogs compared to humans but have been reported, including peripheral facial nerve paralysis, polyradiculoneuritis, and meningitis. Cardiac manifestations such as atrioventricular block are rare. Ocular involvement (uveitis) has been described in isolated case reports.

A survey of seroprevalence of zoonotic vector-borne pathogens in domestic dogs from rural areas in northern Peru by Julca et al. found that B. burgdorferi seropositivity was associated with outdoor housing and lack of ectoparasiticide use, identifying these as important risk factors for exposure [5]. Similarly, Smith et al. reported seroprevalence of selected vector-borne agents in pet cats using a commercial ELISA platform (SNAP 4Dx PLUS) across the United States, and while their focus was feline, the data underscore the importance of passive surveillance in companion animals as sentinels for tick-borne disease risk [11].

Summary of Clinical Signs by Organ System

Diagnostic Considerations

Diagnosis of canine Lyme disease relies on a combination of serologic testing and clinical correlation. The C6 ELISA detects antibodies against a conserved peptide sequence (C6) of the VlsE antigen of B. burgdorferi, which is specific and does not cross-react with other pathogens or vaccine-derived antibodies. Quantitative C6 antibody levels can be used to monitor treatment response and to discriminate between exposure and active infection, though no single cutoff reliably distinguishes subclinical infection from clinical disease.

Polymerase chain reaction (PCR) testing on synovial fluid, blood, or urine can detect spirochete DNA but has limited sensitivity due to the transient nature of spirochetemia. Synovial chemokine and cytokine profiling, as described by Clark et al. in horses with systemic B. burgdorferi infection, may hold promise for future diagnostic applications in dogs, though validated canine panels are not yet commercially available [13].

Differential diagnoses include other tick-borne infections such as anaplasmosis, ehrlichiosis, and babesiosis, as well as non-infectious causes of polyarthritis (e.g., immune-mediated polyarthritis, osteoarthritis). A comprehensive diagnostic workup incorporating complete blood count, serum biochemistry, urinalysis (particularly urine protein:creatinine ratio), and joint fluid analysis is recommended for all suspected cases.

Vaccine Protocols and Prophylaxis

Currently available vaccines for canine Lyme disease are bacterin-based (whole-cell killed) or recombinant OspA vaccines. OspA vaccines target spirochetes within the tick vector: when a vaccinated dog is bitten by an infected tick, the tick ingests anti-OspA antibodies along with the blood meal, which bind to OspA on the spirochete surface and prevent migration from the midgut to the salivary glands, thereby blocking transmission. This mechanism is distinct from traditional vaccines that target the pathogen within the host.

Vaccination is recommended for dogs living in or traveling to endemic areas, particularly in the northeastern, mid-Atlantic, and upper Midwestern United States, as well as parts of Europe and Asia. Primary vaccination involves two doses administered 2 to 4 weeks apart, followed by annual boosters. The duration of protective immunity is generally 12 months, but field efficacy varies depending on challenge intensity and vaccine composition.

A reservoir-targeted OspA oral vaccine for wildlife, described by Schwartz et al., represents an innovative One Health approach to reduce environmental spirochete burden [3]. This vaccine is delivered in baits to rodent reservoirs and has shown efficacy in reducing nymphal infection prevalence in field trials. Such interventions complement direct canine vaccination by lowering the enzootic transmission pressure.

Ectoparasiticide-based prevention remains the cornerstone of Lyme disease prophylaxis. Products that rapidly kill or repel Ixodes ticks before spirochete transmission occurs are highly effective. Geurden et al. showed that sarolaner-based products (Simparica) prevented transmission when administered at labeled doses [7]. Lotilaner-based products (Credelio Quattro) similarly provided high levels of protection in a laboratory challenge model [12]. These data support the use of monthly oral or topical acaricides in combination with vaccination for optimal risk reduction.

The Role of Climate and Ecological Change

Predictive modeling by McDermott et al. has demonstrated that climate change is expanding the geographic range of Ixodes ticks, leading to increased B. burgdorferi prevalence in previously non-endemic regions [4]. Citizen science tick observation initiatives, as described by Sormunen, serve as early warning systems for tick-borne disease emergence by collecting real-time tick encounter data from the public [10]. These data can be integrated into veterinary public health surveillance to guide regional vaccination recommendations.

In Lebanon, Khalife and El Safadi identified that canine seroprevalence to B. burgdorferi was higher in dogs with access to unmanaged vegetation and those not receiving regular acaricide treatment [2]. Such risk factor analyses are essential for designing targeted prevention campaigns in resource-limited settings.

Conclusion

Lyme disease in dogs remains a significant tick-borne zoonotic concern, primarily driven by B. burgdorferi transmission via Ixodes spp. ticks. Clinical signs are dominated by acute polyarthropathy and, less commonly, protein-losing nephropathy. Diagnosis requires serologic confirmation coupled with clinical correlation, and treatment with doxycycline (10 mg/kg every 24 hours for 28 to 30 days) is standard, though recent studies question the necessity of prolonged therapy for subclinical infections. Prevention relies on a dual approach of effective acaricide use and OspA-based vaccination. Ongoing surveillance, including serosurveys in sentinel canine populations and citizen science tick monitoring, will be critical for adapting prevention strategies to changing ecological conditions. The integration of field trial data, molecular diagnostics, and predictive modeling continues to refine our understanding of canine borreliosis and its management.

References

[1] Ye Q, Zhang G, Wang R, et al. Survey of tick species and tick-borne pathogens in pet dogs and cats in mainland China. Vet Parasitol. URL: https://pubmed.ncbi.nlm.nih.gov/42155156/

[2] Khalife S, El Safadi D. Canine vector-borne diseases in Lebanon: Unveiling prevalence trends and risk factors for public health and disease control. Vet Parasitol Reg Stud Reports. URL: https://pubmed.ncbi.nlm.nih.gov/42150803/

[3] Schwartz AM, Henao-Ceballos F, Arnold K, et al. A double-blinded, placebo-controlled field trial of an OspA-based oral reservoir targeted vaccine against Borrelia burgdorferi. NPJ Vaccines. URL: https://pubmed.ncbi.nlm.nih.gov/42115648/

[4] McDermott M, Sarkar S, O'Brien J, et al. Predicting Lyme Disease: A One Health Approach. Pathogens. URL: https://pubmed.ncbi.nlm.nih.gov/42075720/

[5] Julca LA, Salas-Fajardo MY, Guevara S, et al. Seroprevalence of zoonotic vector-borne pathogens in domestic dogs from rural areas in northern Peru. Top Companion Anim Med. URL: https://pubmed.ncbi.nlm.nih.gov/42035833/

[6] Kloster H, Stormo C, Haaland AH, et al. Antibodies against tick-borne pathogens in domestic dogs in Norway: Borrelia burgdorferi sensu lato, tick-borne encephalitis virus, and Anaplasma phagocytophilum. Acta Vet Scand. URL: https://pubmed.ncbi.nlm.nih.gov/41834032/

[7] Geurden T, Holzmer S, Myers JAE, et al. Efficacy of Simparica and Simparica TRIO for the prevention of Borrelia burgdorferi by Ixodes scapularis. Parasit Vectors. URL: https://pubmed.ncbi.nlm.nih.gov/41808193/

[8] Winter S, Meißner R, Prost S, et al. A pseudochromosomal reference genome of the golden jackal, Canis aureus. J Hered. URL: https://pubmed.ncbi.nlm.nih.gov/41786621/

[9] Mayer J. The Use of Apitherapy in Oncological Exotic Pet Medicine. Vet Clin North Am Exot Anim Pract. URL: https://pubmed.ncbi.nlm.nih.gov/41714202/

[10] Sormunen JJ. Citizen Science Tick Observations Serve as an Early Warning System for Tick-Borne Diseases. Zoonoses Public Health. URL: https://pubmed.ncbi.nlm.nih.gov/41699433/

[11] Smith RC, Barrantes Murillo DF, Mitchell J, et al. Seroprevalence of selected vector-borne agents in pet cats using the SNAP® 4Dx® PLUS, United States, 2022-2025. Vet Parasitol Reg Stud Reports. URL: https://pubmed.ncbi.nlm.nih.gov/41354526/

[12] Anderson W, Savadelis MD, Wiseman S, et al. Efficacy of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) chewable tablets in the prevention of Borrelia burgdorferi transmission from infected Ixodes scapularis in dogs. Parasit Vectors. URL: https://pubmed.ncbi.nlm.nih.gov/41353540/

[13] Clark KF, Lemcke RA, Gasiorowski JC, et al. Synovial chemokine and cytokine profiles in horses with and without systemic Borrelia burgdorferi infection. Equine Vet J. URL: https://pubmed.ncbi.nlm.nih.gov/41297916/

[14] Philibert C, Ferrolho J, Gibson MS, et al. The Challenge of Lyme Borreliosis: Knowledge, Attitudes, and Practices in France. Biology (Basel). URL: https://pubmed.ncbi.nlm.nih.gov/41007430/